Doxorubicin and cyclophosphamide for the treatment of canine lymphoma: a randomized,placebo‐controlled study* |
| |
| Authors: | J C Lori T J Stein D H Thamm |
| |
| Institution: | 1. Animal Cancer Center, Colorado State University College of Veterinary Medicine, Fort Collins, CO, USA;2. School of Veterinary Medicine, University of Wisconsin‐Madison, Madison, WI, USA |
| |
| Abstract: | Median survival times (STs) for doxorubicin‐treated canine lymphoma range from 5.7 to 9 months. Because dogs treated with multi‐agent protocols have longer STs, we sought to evaluate whether adding cyclophosphamide would improve outcome in canine lymphoma patients while maintaining an acceptable level of toxicity. Thirty‐two dogs with stage III–V multicentric lymphoma were treated with doxorubicin every 3 weeks for five total cycles and prednisone at a tapering dose for the first 4 weeks. Dogs were randomized to receive either cyclophosphamide or placebo concurrently. Seventeen dogs received doxorubicin and placebo, while 15 dogs received doxorubicin and cyclophosphamide. Response, toxicity, progression‐free interval (PFI) and ST were evaluated. The combination of doxorubicin and cyclophosphamide was well tolerated, causing no increase in adverse events over doxorubicin alone. Despite a numeric improvement in outcome in cyclophosphamide treated dogs, the addition of cyclophosphamide did not result in statistically improved response rate, PFI or ST. |
| |
| Keywords: | adriamycin cancer chemotherapy cytoxan dog |
|
|
